Researchers investigated the effects of CDK4/6i, abemaciclib and palbociclib, on the immunopeptidome at nontoxic levels in breast cancer cell lines using biochemical identification of HLA ligands followed by network analyses.
[Oncoimmunology]
Sorry, but the selected Zotpress account can't be found.